Hospira recall
This article was originally published in The Gray Sheet
Executive Summary
Firm says models of its Symbiq one-channel and two-channel infusion pumps may fail to detect air in the line at the end of an infusion. Delivering air to patients could result in serious injury or death, Hospira notes. FDA classified the recall as Class I, the most serious category, on July 15. Hospira first alerted customers to the problem in April, and gave updated recommendations on June 11. Among them, users should not use polyethylene-lined microbore segment administration sets if other sets are available and should not run solution/medication containers dry; and they should enable the "nearing end of infusion" alarm on the devices or use an "air eliminating filter," if appropriate, the firm recommends. Symbiq pumps can still be used while a permanent fix is identified. Hospira had halted shipments in April to investigate customer complaints (1"The Gray Sheet" May 10, 2010)
You may also be interested in...
Mandatory Baxter Infusion Pump Recall Will Cost Up To $600 Million
Baxter will recall all of its Colleague infusion pumps on the U.S. market at an initial cost of up to $600 million, the firm disclosed May 3
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.